

Invest like a pro, with the pros.



www.capitalideasmedia.com



Morning Need to Know Getting you ready for your investing day

February 10, 2021

Written & curated by the Capital Ideas Media team



CANADIAN ANALYSTS' CALLS

WELL Health Technologies

Corp. (TSX:WELL). Canaccord Genuity analyst Doug Taylor raised his target price on the health tech company to \$12 per share from \$9 with a "Speculative Buy" recommendation, following WELL's announced acquisition of CRH Medical.

"There are a couple of aspects of this pivotal transaction that investors should view positively (shares traded up 12 per cent since)," he said.

"First, the deal more than doubles WELL's revenue base and provides instant scale in the U.S. and a

much more substantial platform to consolidate around in this market. Second, the transaction is financially highly accretive valuing CRH at 2.7 times 2021 estimated consensus EV/Sales vs. WELL 11 times) and 6.5 times 'operating EBITDA' (WELL has only recently crossed into EBITDA profitability). Third, the deal is being financed in large part through a fresh injection of equity into WELL at a premium to its prior trading range (and our prior target); WELL issued \$296-million in equity priced at \$9.80 per share (25 per cent above 5-day WVAP) led by long-time supporter Li Ka-shing."

Keyera Corp. (TSX:KEY). Scotia Capital analyst Robert Hope upgraded the energy infrastructure provider to "Sector Outperform" from "Sector Perform," while increasing his target price to \$29 per share from \$24, as he sees "attractive growth with upside."

"We upgrade Keyera to Sector Outperform given: 1) a strong growth outlook out to 2023/2024; 2) improving environment for its legacy assets; and 3) attractive absolute and relative valuation," the analyst wrote.

"Keyera trades at a discount to the group on a EV/EBITDA basis. Looking forward, we believe that Keyera could narrow this gap as the market gets more comfortable with its growth outlook. There could be further upside if the company secures additional Liquids Infrastructure projects or Marketing returns are higher than expected."



U.S. ANALYSTS' CALLS

Chegg Inc. (NYSE:CHGG). Lake Street analyst Eric Martinuzzi bumped up his price target on the online education platform to \$98 per share from \$85 following a Q4 that he calls "a near-replay of Q3."

Mr. Martinuzzi raised his estimates and price target due to the "robust" Q4 results and upward revision to 2021 guidance.

Ameresco, Inc. (NYSE:AMRC). B. Riley Securities analyst Christopher Souther hiked his price target on the energy efficiency and renewable energy solutions provider to \$72 per share from \$50, while

maintaining a "Buy" rating on the stock.

He wrote that he expects the significant investor interest seen in 2020, and thus far in 2021, drawn to the sustainable energy and technology sector to continue, but he does not expect the multiple expansion seen over the past year to be repeatable as the key driver for shares in 2021.

The analyst sees the Biden infrastructure agenda as likely benefiting the entire group.



STOCKS THAT MAY MOVE

Intact Financial Corporation (TSX:IFC) announced better-than-expected Q4 earnings per share of \$2.55 driven by an 8% growth in premiums.

Calian Group Ltd. (TSX:CGY) reported Q1 revenue that rose 17% year over year to \$116 million along with a 24% increase in adjusted EBITDA to a record \$10.4 million for the quarter.

MARKETS

S&P/TSX and U.S. equity futures are pointing to a higher open Wednesday as investors await more corporate earnings and comments from U.S. Federal Reserve chair Jerome Powell.

CURRENCIES

The Canadian dollar is up 0.04 at 0.7875 (U.S.).

COMMODITIES

West Texas Intermediate crude oil rose 0.6% at \$58.70.

Gold gained 0.2% to \$1,840.40 an ounce.

Please email questions, comments or concerns to:

customercare@capitalideasresearch.com

Access, insight and ideas.

Capital Ideas Media Team

www.capitalideasmedia.com













The information and recommendations made available here ("Information") by CIR and/or all affiliates is for informational purposes only and not to be used or construed as an offer to sell or a solicitation of an offer to buy any services or securities. You further agree that neither Capital Ideas Research will be liable for any losses or liabilities that may be occasioned as a result of the information or commentary provided in the letter. By accessing the site and reading this note, you accept and agree to be bound by and comply with the terms and conditions set out herein. If you do not accept and agree to the terms, you should not use this site or accept this email.

CIR is not registered as an adviser under the securities legislation of any jurisdiction of Canada and provides the Information pursuant to an exemption from the registration requirements that is available in respect of generic advice. The recommendations contained on the site and in this email are not tailored to the needs of particular persons and may not be appropriate for you depending on your financial position or investment goals or needs. You should apply your own judgment in making any use of the Information, especially as the basis for any investment decision. Prior to making any investment decision, we recommend that you seek outside advice from a qualified and registered investment advisor.

In no event will CIR be responsible or liable to you or any other party for any damages of any kind arising out of or relating to the use of, misuse of or inability to use this site and email. The Information is directed only at persons resident in Canada. Nothing in this site shall constitute an offer or solicitation to anyone in the United States of America or any jurisdiction where such offer or solicitation is not authorized or to any person to whom it is unlawful to make such a solicitation. If you choose to access this site or email from outside of Canada, you acknowledge that the Information is intended for use by persons resident in Canada only.

This is not an investment advisory, and should not be used to make investment decisions. Information in CIR is often opinionated and should be considered for information purposes only. No stock exchange anywhere has approved or disapproved of the information contained herein. There is no express or implied solicitation to buy or sell securities. The writers and editors of CIR may have positions in the stocks discussed above and may trade in the stocks mentioned. Don't consider buying or selling any stock without conducting your own due diligence.

You are receiving this email because you are part of our investment network.

This email was sent to << Email Address>>

This email was sent to <<u>Email Address>></u>

<u>why did I get this?</u> <u>unsubscribe from this list</u> <u>update subscription preferences</u>

Capital Ideas Research · HSBC Bank Place · 10250 101 Street Suite 1803 · Edmonton, Alberta T5G 3P4 · Canada